{'fraction_non_alphanumeric': 0.02022058823529412, 'fraction_numerical': 0.011029411764705883, 'mean_word_length': 5.405882352941177, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effectiveness and tolerance of the selective MAO-A inhibitor moclobemide in children with hyperkinetic syndrome].

The pharmacotherapy of the hyperkinetic syndrome with amphetamines was inaugurated by Bradley in 1937. As a rule, methylphenidate is prescribed today, although some side effects limit its use. Tests carried out by Zametkin in 1985 showed that clorgyline and tranylcypromine are effective in hyperkinetic children, but not deprenyl. In an open clinical study we administered moclobemide, a new reversible MAO-A inhibitor, to children who fulfilled the diagnostic criteria for hyperkinetic syndrome according to ICD-9 (314). An extensive examination was made to evaluate the efficacy and safety of the substance in this disorder. In addition to subjective ratings on the behavioral level a number of objective neuropsychological tests were used. Moclobemide proved to be effective in the treatment of the hyperkinetic syndrome, and side effects were surprisingly rare. EEGs performed during treatment showed a considerable decrease in delta waves in the frontal lobe region.